Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from BioNTech SE ( (BNTX) ) is now available.
On March 10, 2026, BioNTech announced that co-founders Ugur Sahin and Özlem Türeci will establish an independent biotechnology company dedicated to next-generation mRNA innovations, with a management transition targeted by the end of 2026. BioNTech plans to transfer certain rights and mRNA technologies to the new venture in exchange for a minority stake and potential milestone and royalty streams, while preserving opportunities for future collaboration on combination therapies.
The move is part of BioNTech’s strategy to sharpen its focus on developing and commercializing its expanding late-stage pipeline, including immunomodulators, ADCs and mRNA candidates, as it works toward becoming a commercial multi-product company by 2030. The company said its existing clinical programs, including its COVID-19 vaccine franchise and an expected 15 Phase 3 oncology trials by year-end 2026, will remain unaffected, and its supervisory board has begun searching for successors to ensure leadership continuity and operational stability during the founders’ transition.
The most recent analyst rating on (BNTX) stock is a Buy with a $134.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
BioNTech’s overall stock score reflects a challenging financial performance with recent losses, offset by a strong balance sheet and strategic advancements in oncology. Technical indicators suggest a neutral trend, while valuation remains unattractive due to negative earnings. The earnings call provided positive guidance, but regulatory delays and financial losses remain concerns.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a German global next-generation immunotherapy company focused on novel therapies for cancer and other serious diseases. It develops mRNA cancer immunotherapies, next-generation immunomodulators, antibody-drug conjugates and CAR-T cell therapies, and is also advancing multiple mRNA vaccine candidates for infectious diseases through collaborations with major pharmaceutical partners.
Average Trading Volume: 939,765
Technical Sentiment Signal: Strong Sell
Current Market Cap: $24.56B
See more insights into BNTX stock on TipRanks’ Stock Analysis page.